Vpriv OverviewVelaglucerase alfa (trade name VPRIV), manufactured by Shire plc is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase indicated as a long-term enzyme replacement therapy for those suffering of Gaucher disease Type 1. It has an identical amino acid sequence to the naturally occurring enzyme. It was approved for use by the U.S. Food and Drug Administration (FDA) on February 26, 2010. Competitive pr...
Read more Vpriv Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Velaglucerase_alfa
Recent Vpriv Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 200units, 400 units/vial, 400units
- Powder: 200 units/vial
NDC Database Records for Vpriv: (1 result)Sorted by National Drug Code
- 54092-701 Vpriv 2.5 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Shire Us Manufacturing Inc.